A phase 3 randomized trial found that Mim8 prophylaxis significantly reduced bleeding rates compared with on-demand therapy and clotting factor prophylaxis in patients with hemophilia A with or without...
An individual participant data meta-analysis clarifies which elements of collaborative care most effectively reduce depressive symptoms in primary care, informing implementation strategies for clinicians...
April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...
A randomized clinical trial in Pakistan evaluated whether structured, measurement-based care could accelerate antidepressant response and remission in adults with major depressive disorder compared with...
On May 1, the FDA approved vepdegestrant (Veppanu), a heterobifunctional protein degrader, for adults with estrogen receptor–positive, human epidermal growth factor receptor 2–negative, ESR1-mutated...
A randomized clinical trial evaluated whether a 6-month habit-focused lifestyle program could improve sustained remission of metabolic syndrome at 24 months compared with standard education and activity...
The FDA has approved dextromethorphan-bupropion extended-release tablets for agitation associated with Alzheimer disease dementia, offering clinicians a non-antipsychotic treatment option supported by...
The FDA has approved a supplemental indication for lumateperone to reduce relapse risk in adults with schizophrenia based on phase 3 randomized withdrawal data.
